Fig. 4

Fig. 4 Potency of the 2-drug combinations evaluated by SynergyFinder using inhibition (%) scores.

A Bortezomib + nedaplatin was a very potent drug combination and inhibited CAL-148 with a mean (47.9) and median (60.0) inhibition score. B Carboplatin + paclitaxel had the lowest inhibition scores, mean (13.4) and median (14.3). C Carboplatin + paclitaxel had the highest mean and median inhibition on the MDA-MB-468 cell line. D Bortezomib + nedaplatin had the highest inhibition on the HCC38 cell line and lowest inhibition on HCC1806. E Bortezomib + nedaplatin achieved 34.3% above maximal inhibition by bortezomib alone and F carboplatin + paclitaxel achieved 7.7% above the maximal inhibition by paclitaxel alone. Paired t-test was used to calculate statistically significant differences between inhibition following monotherapy or with 2-drug combinations. *P < 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.